From prolactin cell to prolactinoma: Implications of ontogenic mechanisms in diagnosis and management

Endocrine-Related Cancer

Volumn 5, Issue 1, 1998, Pages 27-36

  Velkeniers, B ^a   Hooghe Peters, E L ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b FACULTY OF MEDICINE AND PHARMACY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ORAL CONTRACEPTIVE AGENT;

CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALIGNANT TRANSFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONTOGENY; PATHOGENESIS; PROLACTIN SECRETING CELL; PROLACTINOMA; REVIEW; TUMOR GROWTH;

EID: 0031982243     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050027     Document Type: Review

References (104)

1. Abe H, Engler D, Molitch ME, Bollinger-Gruber J & Reichlin S 1985 Vasoactive intestinal peptide is a physiological mediator of prolactin release in the rat. Endocrinology 116 1383-1390.
2. Alexander JM, Swearingen B, Tindall GT & Klibanski A 1995 Human pituitary adenomas express endogenous inhibin subunit and follistatin messenger ribonucleic acids. Journal of Clinical Endocrinology and Metabolism 80 147-152.
3. Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr & Klibanski A 1996 Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-β receptors in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 81 783-790.
4. Bachmann GA & Kemmann E 1982 Prevalence of oligomenorrhea and amenorrhea in a college population. American Journal of Obstetrics and Gynecology 144 98-102.
5. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV & Clayton RN 1997 Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 82 818-824.
6. Beckers A, Abs R, Reyniers E, De Boulle K, Stevenaert A, Heller FR, Klöppel G, Meurisse M & Willems PJ 1994 Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. Journal of Clinical Endocrinology and Metabolism 79 1498-1502.
7. Ben-Jonathan N & Liu JW 1992 Pituitary lactotrophs, endocrine, paracrine, juxtacrine, and autocrine interactions. Trends in Endocrinology and Metabolism 3 254-258.
8. Bevan JS, Webster J, Burker CW & Scanlon MP 1992 Dopamine agonists and pituitary tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 13 220-240.
9. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P, Perrett CW, Thakker RV & Clayton RN 1994 Molecular genetic studies of sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism 78 387-392.
10. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L & Greenaway TM 1996 Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. Journal of Clinical Endocrinology and Metabolism 81 1841-1845.
11. Burris TP, Stringer LS & Freeman ME 1991 Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. Neuroendocrinology 54 175-183.
12. Burrow GN, Wortzmann G, Rewcastle NB, Holgate RC & Kovacs K 1981 Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New England Journal of Medicine 304 156-168.
13. Bussen S, Brosemann N & Steck T 1996 Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity. Gynecological Endocrinology 10 83-90.
14. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C & Enjalbert A 1994 Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60 314-322.
15. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P & Enjalbert A 1996 Alteration of G alpha subunits mRNA levels in bromocriptine-resistant prolactinomas. Journal of Neuroendocrinology 8 737-746.
16. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT & Klibanski A 1994 ras mutations in human prolactinomas and pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 78 89-93.
17. Carillo AJ, Pool TB & Sharp ZD 1985 Vasoactive intestinal peptide increases prolactin messenger ribonucleic acid content in GH3 cells. Endocrinology 116 1202-1206.
18. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang T, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Rester MB, Young SK, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-407.
19. Ciccarelli E & Camanni F 1996 Diagnosis and drug therapy of prolactinoma. Drugs 51 954-965.
20. Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D & Lombardi G 1995 Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Hormone Research 44 222-228.
21. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L & Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 82 876-883.
22. Cronin MJ 1982 The role and direct measurement of the dopamine receptor(s) in the anterior pituitary. In Neuroendocrine Perspectives, vol 1, pp 169. Eds ER Muller & RM MacLeod. Amsterdam: Elsevier.
23. De Greef WJ & Visser TJ 1981 Evidence for the involvement of hypothalamic dopamine and thyrotrophin-releasing hormone in suckling-induced release of prolactin. Journal of Endocrinology 191 213-223.
24. Delgrange E, Maiter D & Donckier J 1996 Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. European Journal of Endocrinology 134 454-456.
25. Delhase M, Vergani P, Malur A, Velkeniers B, Teugels E, Trouillas J & Hooghe-Peters EL 1993 Pit-1/GHF-1 expression in pituitary adenomas: further analogy between adenomas and rat SMtTW tumours. Journal of Molecular Endocrinology 11 129-139.
26. Demura R, Kubo O, Suzuki T, Yajima R, Tajima S, Takakura K, Demura H, Aiba M & Eto Y 1996 Demonstration of activin in normal pituitary and in various human pituitary adenomas by immunohistochemistry. Endocrine Journal 43 429-432.
27. Elias KA & Weiner RI 1983 Direct arterial vascularization of estrogen-induced prolactin secreting anterior pituitary tumors. Proceedings of the National Academy of Sciences of the USA 82 4549-4553.
28. Enjalbert A, Ruber M, Arancibia S, Fiore L, Priam M & Kordon C 1979 Independent inhibition of prolactin secretion by dopamine and gamma-aminobutyric acid in vitro. Endocrinology 105 823-826.
29. Ezzat S, Smyth HS, Ramyar L & Asa SL 1995 Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 878-884.
30. Faglia G 1993 Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinologica 129 (Suppl 1) 1-5.
31. Feek CM, McLelland J, Seth J, Toft AD, Irvine WJ, Padfield PL & Edwards CR 1984 How effective is external pituitary irradiation for growth hormone secreting pituitary tumours? Clinical Endocrinology 20 401-408.
32. Garcia MM & Kapcala LP 1995 Growth of microprolactinoma to a macroprolactinoma during estrogen therapy. Journal of Endocrinological Investigation 18 450-455.
33. Gonzalez JG, Elizondo G, Salvador D, Namez H, Todd LE & Villareal JZ 1988 Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. American Journal of Medicine 85 217-220.
34. Grandison L & Guidotti A 1979 Gamma-aminobutyric acid receptor function in rat anterior pituitary: evidence for control of prolactin release. Endocrinology 105 754-759.
35. Green VL, Atkin SL, Speirs V, Jeffreys RV, Landolt AM, Mathew B, Hipkin L & White MC 1996 Cytokine expression in human anterior pituitary adenomas. Clinical Endocrinology 45 179-185.
36. Hall WA, Luciano MG, Doppman JL, Patronas NJ & Oldfield EH 1994 Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Annals of Internal Medicine 120 817-820.
37. Hazlerigg DG, Hastings MH & Morgan PJ 1996 Production of prolactin releasing factor by ovine pars tuberalis. Journal of Neuroendocrinology 8 489-492.
38. Herman V, Prazin NZ, Gonsky R & Melmed M 1993 Molecular screening of pituitary adenomas for gene mutations and rearrangements. Journal of Clinical Endocrinology and Metabolism 77 50-55.
39. Hofland U, Velkeniers B, van de Lely AJ, Van Koetsveld PM, Kazemzadeh M, Waaijers M, Hooghe-Peters EL & Lamberts SWJ 1992 Long-term in vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH-mRNA levels. Clinical Endocrinology 37 240-248.
40. Horvath E & Kovacs K 1980 Pathology of the pituitary gland. In Pituitary Diseases, pp 1-83. Eds K Kovacs, C Ezrin, MH Weiss, E Horvath & B Karyman. Boca Raton, FL: CRC Press.
41. Horvath E & Kovacs K 1994 Morphology of adenohypophyseal cells and pituitary adenomas. In The Pituitary Gland, pp 29-62. Ed. H Imura. New York: Raven Press.
42. Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L & Gulino A 1996 Cellular receptors for sex steroids in human pituitary adenomas. Journal of Endocrinology 151 175-184.
43. Jamrozik SI, Bennett AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C & Louvet JP 1996 Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. Journal of Endocrinological Investigation 19 472-479.
44. Jeffcoate WJ, Pound N, Sturrock NPC & Lambourne J 1996 Long-term follow-up of patients with hyperprolactinemia. Clinical Endocrinology 45 299-303.
45. Kato Y, Iwasaki Y, Iwasaki J, Abe H, Yanaihara N & Imura H 1978 Prolactin release by vasoactive intestinal peptide in rats. Endocrinology 103 554-558.
46. Kazemzadeh M, Velkeniers B, Herregodts P, Collumbien R, Finné E, Derde MP, Vanhaelst L & Hooge-Peters EL 1992 Differential dopamine-induced prolactin mRNA levels in various prolactin-secreting cell (sub)populations. Journal of Endocrinology 132 401-409.
47. Kobrin MS, Asa SL, Samsoondar J & Kudlow JE 1987 α-Transforming growth factor in the bovine anterior pituitary gland: secretion by dispersed cells and immunohistochemical localization. Endocrinology 121 1412-1416.
48. Kojima Y, Arita J, Kuwana N & Kimura F 1995 Dopamine responsiveness of human prolactinoma cells as determined by the reverse hemolytic plaque assay. Endocrine Journal 42 355-360.
49. Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC & Loriaux DL 1984 Hyperprolactinemia, amenorrhea and galactorrhea. A retrospective assessment of twenty-five cases. Annals of Internal Medicine 100 115-121.
50. Kupersmith MJ, Rosenberg C & Kleinberg D 1994 Visual loss in pregnant women with pituitary adenomas. Annals of Internal Medicine 121 473-477.
51. Lamberts SWJ & MacLeod RM 1978 Studies on mechanisms of GABA-mediated inhibition of prolactin secretion. Proceedings of the Society for Experimental Biology and Medicine 158 10-13.
52. Le Dafniet M, Blumberg-Tick J, Gozlan H, Barret A, Joubert Bression D & Peillon F 1989 Altered balance between thyrotropin-releasing hormone and dopamine in proIactinomas and other pituitary tumors compared with normal pituitaries. Journal of Clinical Endocrinology and Metabolism 69 267-271.
53. LeRiche VK, Asa SL & Ezzat S 1996 Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. Journal of Clinical Endocrinology and Metabolism 81 656-662.
54. Lloyd HM, Jacobi JM & Willgoss DA 1995 DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Clinical Endocrinology 43 79-85.
55. Lloyd RV 1983 Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland: an immunocytochemical study. American Journal of Pathology 113 198-206.
56. Lloyd RV & Landefeld TD 1986 Detection of prolactin messenger RNA in rat anterior pituitary by in situ hybridization. American Journal of Pathology 125 35-44.
57. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ & Kudlow JE 1995 Targeting of transforming growth factor-α expression to-pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 136 4479-4488.
58. MacLeod RM & Lehmeyer JE 1974 Studies on the mechanisms of dopamine-mediated inhibition of prolactin secretion. Endocrinology 94 1077-1085.
59. Maraschini C, Moro M, Toja P, Braga M & Cavagnini F 1996 No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration. Gynecological Endocrinology 10 7-15.
60. Martin TL, Kim M & Malarkey WB 1985 The natural history of idiopathic hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism 60 855-858.
61. 2+/protein kinase C pathway. Neuroendocrinology 47 38-45.
62. Massoud F, Serri O, Hardy J, Somma M & Beauregard H 1996 Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surgical Neurology 45 341-346.
63. Maurer RA & Gorski J 1977 Effects of estradiol-17β and pimozide on prolactin synthesis in male and female rats. Endocrinology 101 76-84.
64. Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C et al. 1994 Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecological Endocrinology 8 175-181.
65. Mindermann T & Wilson CB 1994 Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 41 359-364.
66. Mogg RJ & Samson WK 1990 Interactions of dopaminergic and peptidergic factors in the control of prolactin release. Endocrinology 126 728-735.
67. Molitch ME 1985 Pregnancy and the hyperprolactinaemic woman. New England of Medicine 312 1365-1370.
68. Molitch ME 1986 Manifestations, epidemiology and pathogenesis of prolactinomas in women. In Prolactinomas, p 78. Eds JM Olofsky and RJ Robbin. New York: Churchill Livingstone.
69. Molitch ME 1987 Pathogenesis of pituitary tumors. Endocrinology and Metabolism Clinics of North America 16 503-527.
70. Molitch ME 1995 Prolactin. In The Pituitary, pp 136-186. Ed. S Melmed. Cambridge, MA:Blackwell Science.
71. Molitch ME & Russell EJ 1990 The pituitary incidentaloma. Annals of Internal Medicine 112 925-931.
72. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J & Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of 2 prospective multicenter study. Journal of Clinical Endocrinology and Metabolism 60 698-705.
73. Molitch ME, Thorner MO & Wilson C 1997 Therapeutic controversy. Management of prolactinomas. Journal of Clinical Endocrinology and Metabolism 82 996-1000.
74. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A & Jaquet P 1996 Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology 135 413-420.
75. Murdoch GH, Potter E, Nicolaisen AK, Evans RM & Rosenfeld MG 1982 Epidermal growth factor rapidly stimulates prolactin gene transcription. Nature 300 192-194.
76. Otten P, Rilliet B, Reverdin A, Demierre B & Berney J 1996 Pituitary adenoma secreting prolactin. Results of their surgical treatment. Neurochirurgie 42 44-53.
77. Pei L, Melmed S, Scheithauer B, Kovacs K & Prager D 1994 Hras mutations in human pituitary carcinoma metastases. Journal of Clinical Endocrinology and Metabolism 78 842-846.
78. Pellegrini-Bouiller I, Morange-Ramos I, Earlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P & Enjalbert A 1996 Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. Journal of Clinical Endocrinology and Metabolism 81 3390-3396.
79. Plotsky PM & Neill JD 1982 Interactions of dopamine and thyrotrophin releasing hormone in the regulation of prolactin release in lactating rats. Endocrinology 111 168-173.
80. Plowman PN 1995 Radiotherapy for pituitary tumours. Baillière's Clinical Endocrinology and Metabolism 9 407-420.
81. Rhodes SJ, di Mattia GE & Rosenfeld MG 1994 Transcriptional mechanisms in anterior pituitary cell differentiation. Current Opinions in Genetics and Development 4 709-717.
82. Ross RJM, Grossman A, Bouloux P, Rees LH, Doniach L & Besser GM 1985 The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with macroadenoma. Clinical Endocrinology 23 227-235.
83. Schlechte JA 1995 Clinical impact of hyperprolactinaemia. In Baillière's Clinical Endocrinology and Metabolism. Pituitary Tumors, pp 359-360. Ed. JA Fagin.
84. Schlechte J, El-Khoury G, Kathol M & Walkner L 1987 Forearm and vertebral bone mineral content in treated and untreated hyperprolactinemic amenorrhea. Journal of Clinical Endocrinology and Metabolism 64 1021-1026.
85. Schlechte JA, Dolan K, Sherman B, Chapler F & Luciano A 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. Journal of Clinical Endocrinology and Metabolism 68 412-418.
86. Shanis BS & Check JH 1996 Relative resistance of a macro prolactinoma to bromocriptine therapy during pregnancy. Gynecological Endocrinology 10 91-94.
87. Shimon I, Huttner A, Said J, Spirina OM & Melmed S 1996 Heparin-binding secretory transforming gene (hst) facilitates rat lacrotrope cell tumorigenesis and induces prolactin gene transcription. Journal of Clinical Investigation 97 187-195.
88. Soule SG, Powell M & Jacobs HS 1994 Prolactinomas resistant to dopamine agonists: insights into pathogenesis and therapy. Current Opinion in Obstetrics and Gynecology 6 393-397.
89. Soule SG, Farhi J, Conway GS, Jacobs HS & Powell M 1996 The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clinical Endocrinology 44 711-716.
90. Spona J, Leibl H & Bieglmayer C 1980 Nuclear translocation of estrogen-receptor complex and stimulation of RNA synthesis by estrogens of different biological potencies in the female rat pituitary. Biochimica et Biophysica Acta 607 189-200.
91. Stadnik T, Spruyt D, van Binst A, Luypaert R, D'Haens J & Osteaux M 1994 Pituitary microadenomas: diagnosis with dynamic serial CT, conventional CT and T1-weighted MR imaging before and after injection of gadolinium. European Journal of Radiology 18 191-198.
92. Tatsumi K, Miyai K, Notomi T, Kaibl K, Amino N & Mizuno Y 1992 Cretinism with combined hormone deficiency caused by a mutation in the Pit-1 gene. Nature Genetics 1 56-58.
93. Thomson JA, Davies DL, McLaren EH & Teasdale GM 1994 Ten year follow-up of microprolactinoma treated by transsphenoidal surgery. British Medical Journal 306 1409-1410.
94. Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H & Thalassinos N 1995 Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Clinical Endocrinology 42 593-599.
95. Vallar L, Spada A & Giannatos G 1987 Altered GS and adenylate cyclase activity in human GH secreting adenomas. Nature 330 566-568.
96. Velkeniers B, Hooghe-Peters EL, Hooghe R, Belayew A, Smets G, Robberecht P & Vanhaelst L 1988 Prolactin cell subpopulations separated on discontinuous Percoll gradient: an immunocytochemical, biochemical and physiological characterization. Endocrinology 123 1619-1630.
97. Velkeniers B, Kazemzadeh M, Vanhaelst L & Hooghe-Peters EL 1994a Functional heterogeneity with respect to oestrogen treatment in prolactin cell subpopulations separated by Percoll gradient centrifugation. Journal of Endocrinology 141 251-258.
98. Velkeniers B, Vergani P, Trouillas J, D'Haens J, Hooghe RJ & Hooghe-Peters EL 1994b Expression of IL-6 mRNA in normal and human pituitaries and in human pituitary adenomas. Journal of Histochemistry and Cytochemistry 42 67-76.
99. Velkeniers B, Haitsma V, D'Haens J & Vanhaelst L 1996 Surgical outcome of preoperative bromocriptine treatment in micro prolactinomas. XXIII International Congress of Internal Medicine (ISIM), Manila, Philippines, February 1-6, 1996. (Oral Communication).
100. Voges J, Sturm V, Deuss U, Traud C, Treuer H, Schlegel W, Winkelmann W & Mueller RP 1996 LINAC-radiosurgery (LINAC-RS) in pituitary adenomas: preliminary results. Acta Neurochirurgien (Wien) Suppl 65 41-43.
101. Webster J 1996 A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety 14 228-238.
102. Webster J & Scanlon MF 1991 Growth factors and the anterior pituitary. Baillière's Clinical Endocrinology and Metabolism 5 699-726.
103. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhea. New England Journal of Medicine 331 904-909.
104. Wingrave SJ, Kay CR & Vessey MP 1980 Oral contraceptives and pituitary adenomas. British Medical Journal 1 685-686.